18 November 2025

ReNeuron Group plc
("ReNeuron" or the "Company")

Shareholder update

ReNeuron Group, a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery systems, provides an operational update, detailing commercial progress for its CustomEX™ platform and catalogue of established cell lines.

Randolph Corteling, Managing Director and Chief Scientific Officer of ReNeuron Group commented: *"Since we announced ReNeuron's exit from Administration in March 2025, we have continued to progress the new streamlined business with our CustomEX™ platform. We have a good cash runway and a cost-effective R&D based business model to support a strong pipeline of commercial opportunities and licensing agreements. In the coming months we will look to generate new revenue streams and as we expand, establish a new facility in South Wales to continue our progress and diversify our portfolio. Going forward we will continue to update shareholders on our progress and ultimately look to return value to our shareholders."*

A new Company website is available here: www.reneuron.com

Introduction
The Company's mission, through its CustomEX™ platform, remains in overcoming barriers to drug delivery and driving therapeutic innovation. The Company is confident that the CustomEX™ platform will enable the targeted delivery of advanced therapeutic modalities, such as siRNA, mRNA and gene editing complexes, with the potential to develop the next generation of gene therapies for previously untreatable diseases of the central nervous system, lungs and kidney. The Company's aim is to the license its distinct cell lines, allowing for the realisation of a cost-effective R&D business model and new revenue streams within the business.

ReNeuron considers there to be significant untapped potential in making a proportion of its established stem cell lines available for research and development, whilst also building relationships with third parties to overcome their drug delivery challenges by utilising CustomEX™. In addition, the Company will use its extensive knowledge and expertise to further develop the CustomEX™ platform, allowing for a tailored approach of selecting the appropriate delivery vehicle to ensure successful delivery of the chosen drug to its target.

CustomEX™ - Overcoming barriers to drug delivery
CustomEX™ is a customisable, exosome-based, targeted drug delivery platform for modern therapeutics which exploits the natural function of stem cell-derived exosomes to target specific cells and tissues. The platform has the potential to overcome the limitations of traditional delivery platforms, such as penetration across biological barriers, immunogenicity, and lack of cellular targeting. Unlike others in the field, CustomEX™ is made up of multiple proprietary conditionally immortalised stem cell-derived exosome producer lines, with a proven track record of the consistent and scalable manufacture of stem cell lines. Each cell line produces unique exosomes which can overcome biological barriers and have distinct tissue and cellular targeting capabilities.

Delivery continues to be a major hurdle that holds back the clinical development of many complex drug modalities. In particular, the effective and safe targeting of extrahepatic tissues remains a significant obstacle for the development and translation of advanced therapeutics from the lab to the clinic. Despite huge advances in the field, there are a staggering number of diseases that do not have a developed treatment, which is partly due to there being a lack of appropriate cell models. These diseases continue to burden healthcare systems and contribute to global deaths rates. ReNeuron's CustomEX™ platform presents a strong solution and opportunity in the targeted



delivery of advanced therapeutic modalities, featuring proprietary loading technology for a variety of therapeutic cargos, including small molecular weight drugs, proteins, and nucleic acids.

New data has confirmed *in-vitro* and *in-vivo* that exosome targeting is dependent on cell sources and that the selection of specific exosome populations result in the improved delivery of therapeutic payloads when compared to conventional approaches. Recent *in-vivo/ex-vivo* studies have also confirmed:

- A specific CustomEX™ exosome targets the lung following systemic administration.
- A specific CustomEX™ exosome selectively targets the tubules within the kidney.
- A specific CustomEX™ exosome targets the CNS.
- Successful targeted delivery of a therapeutic payload in vivo using the CustomEX™ platform following systemic delivery.
- No sign of toxicity or immune response, opening the possible use of CustomEX™ for repeat administration unlike viral vectors.

The opportunity to make these cell lines available for licensing will allow ReNeuron to **generate new revenue streams** for the Company**.** Each cell line will be made available on a non-exclusive basis for an annual licence fee, either for research or in a commercial setting. Due to the established nature of these lines, these cell lines provide a ready to go product, which will allow for the fast establishment of revenue generation. Notably, the CustomEX™ platform itself uses distinct cell lines to those that will be made available for collaboration and licensing deals to generate revenue – therefore having no impact on the core development of the platform.

Established cell lines

ReNeuron can offer over twenty research grade equivalent cell lines, developed from a variety of tissues, using the same immortalisation technology developed for the Company's clinical programmes. Cell lines which can be utilised immediately for R&D purposes include:

- CNS focused – Cortical, Hippocampal, Striatal, Spinal Cord, Ventral Mesencephalon, Cerebellum
- Other cell types – Liver, Pancreatic, Retinal

These immortalised cells offer key advantages over other cell lines, such as growth characteristics (retention of replicative capacity), good population doubling rates, stability, and established growth conditions. Additionally, many of these cells have been characterised in terms of their morphology and marker expression, which is comparable to primary cells, as well as being evaluated for adventitious agents. A selection of the cell lines have a proven track record and are already considered invaluable for both in vitro and in vivo studies. There is extensive research supporting their unique capabilities and use within the pharmaceutical industry, particularly those that are commercially available through Millipore (ReNcell CX and ReNcell VM), in addition to a small number of cell lines which have been specifically released to academic institutions.

Advantages of ReNeuron's technology

A key challenge in drug discovery has been a historical lack of good model cell lines for primary screening. Certain cell types, such as neuronal cells, are not accessible for *ex vivo* screening approaches. Therefore, many cell models are based on cancer cell lines, which have numerous genetic changes compared to the cell type of interest and are normally not representative of the disease of interest. The current go-to technology for the development of specific lines for cell-models (both for screening and efficacy evaluation) are induced pluripotent stem cells (iPSCs). Even though iPSCs have proved successful in certain scenarios, they inflict a huge cost for development, involve time-consuming protocols and suffer from heterogeneity within their cell populations. Furthermore, there is often variability between batches of differentiated cells and even a small change in growth conditions can lead to



unwanted spontaneous differentiation or changes in growth characteristics. All these factors are a hindrance to the development of iPSCs platforms.

ReNeuron's technology is not only unique and protected by extensive expertise, but also provides a significant advantage over traditional models, such as these iPSC methods. Benefits of the platform includes the ease of culture, stability, replicative capacity and availability of patient and genotype matched cell types (controls). This collectively offers new opportunities for cell-based models in the following applications:

- Target engagement/validation
- High throughput screening of advanced therapies
- Identification of off target effects
- Novel target discovery
- Predict interactions and off target effects
- Predict safety and toxicological testing
- Lead optimisation and efficacy evaluation
- Development of 2D and 3D cell models – co-culture with patient matched cells

Progress & Outlook

The Directors are pleased with the progress of the Company over the last 6 months. Negotiations regarding a licensing agreement for the Company's cell lines is progressing well and other commercial opportunities remain in active discussions. The potential to establish further proof of concept data in a cost-effective manner for the CustomEX™ platform, whilst retaining a strong connection with South Wales remains a distinct possibility and further updates will be provided in due course.

Information re. share ownership

The Company's shares are no longer publicly traded and the Directors have been unable to establish a cost-effective or efficient means for shareholders to establish a market value for these shares beyond nominal value (1 pence) or a mechanism to trade their shares privately.

If shareholders do wish to dispose of their shares at nominal value then please contact the Company via Walbrook PR.

To register to receive ongoing investor communications from ReNeuron please email: reneuron@walbrookpr.com

Enquiries:

ReNeuron Group plc **Via Walbrook PR**
Iain Ross, Chairman
Randolph Corteling, Managing Director & Chief Scientific Officer

Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 or Mob: +44 (0)7980 541 893